This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Conglomerate 3M’s focus on business transformation — with moves like the localization of decision making and integration of supply chains — enhances its competitive advantage. Also, its recognized product brands and investments in innovation are compelling. Inorganic actions (buyouts and divestments) are added advantages. Acelity, bought in October 2019, is predicted to aid 3M’s medical solutions business. Being one of the largest manufacturers of respiratory masks, the coronavirus outbreak has added to the company’s growth potential.
3M (MMM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
3M (MMM) closed at $165.66 in the latest trading session, marking a +0.96% move from the prior day.
Why Is 3M (MMM) Up 4.9% Since Last Earnings Report?
by Zacks Equity Research
3M (MMM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3M (MMM) Unveils Virtual Assistant Technology for Epic Users
by Zacks Equity Research
3M (MMM) introduces 3M M*Modal virtual assistant technology for Epic customers, which will make the process of electronic health record documentation simpler, faster and more effective for clinicians.
Industrial ETFs Are Gaining Despite Mixed Q2 Earnings
by Sweta Jaiswal, FRM
We discuss the impact of Q2 earnings releases of some major players on industrial ETFs with heavy exposure to the same.
The Zacks Analyst Blog Highlights: Home Depot, AbbVie, Broadcom, 3M and Morgan Stanley
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Home Depot, AbbVie, Broadcom, 3M and Morgan Stanley
3M (MMM) Sales Rise Y/Y in July, Quarterly Dividend Approved
by Zacks Equity Research
3M's (MMM) sales performance in July is driven by strengthening product demand despite the prevailing pandemic difficulties. Also, it receives approval for the quarterly dividend payment.
S&P Shoots for All-Time Highs Again
by Jeremy Mullin
Bulls target S&P 3400 by weeks end.
Top Analyst Reports for Home Depot, AbbVie & Broadcom
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including The Home Depot (HD), AbbVie (ABBV) and Broadcom (AVGO).
The Zacks Analyst Blog Highlights: Apple, AT&T, Target, Honeywell and 3M
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, AT&T, Target, Honeywell and 3M
Stock Market News for Jul 29, 2020
by Zacks Equity Research
Benchmarks slipped into the negative territory on Tuesday as investors kept a close watch on a second coronavirus relief package in consideration by lawmakers, along with mixed second-quarter corporate earnings report.
Buy Caterpillar Stock Ahead of Q2 Earnings, Stay for the Dividend?
by Benjamin Rains
Caterpillar is set to release its second quarter fiscal 2020 financial results before the opening bell on Friday, July 31. Is it time to buy CAT stock?
3 Cheap Gold & Silver Stocks to Buy Right Now as Haven Prices Surge
by Benjamin Rains
It might be time for investors to take advantage of rising gold and silver prices. Let's dive into three such stocks trading under $20 per share that could be enticing...
All Eyes on "The Swamp;" Plus Q2 Reports from PFE, MCD & More
by Mark Vickery
Senate Republicans on Capitol Hill have unveiled their long-awaited stimulus package to replace the CARES Act, which expires at the end of this week. Also, the Fed begins a two-day session.
HEALS Act & Earnings Data Deluge
by Zacks Equity Research
HEALS Act & Earnings Data Deluge
3M (MMM) Q2 Earnings Surpass Earnings, Fall Y/Y on Weak Sales
by Zacks Equity Research
3M's (MMM) second-quarter 2020 results reflect the adverse impacts of the coronavirus outbreak, forex woes and inorganic actions, offset by lower taxes, a fall in share count and cost reduction.
3M (MMM) Q2 Earnings Top Estimates
by Zacks Equity Research
3M (MMM) delivered earnings and revenue surprises of 0.56% and -1.27%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Q2 Scorecard and Research Reports for Apple, AT&T & Target
by Sheraz Mian
In addition to a real-time scorecard for the Q2 earnings season, today's Research Daily features new research reports on 1Apple (AAPL), AT&T (T) and Target (TGT) and others.
General Electric (GE) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
General Electric's (GE) Q2 results are expected to reflect the coronavirus adversity on its businesses. Solid liquidity, pepped-up demand for some products and debt reduction are likely tailwinds.
Should You Buy 3M (MMM) Ahead of Earnings?
by Zacks Equity Research
3M (MMM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
3M (MMM) Gains As Market Dips: What You Should Know
by Zacks Equity Research
3M (MMM) closed the most recent trading day at $159.84, moving +0.35% from the previous trading session.
Is a Beat in Store for 3M Company (MMM) This Earnings Season?
by Zacks Equity Research
3M Company's (MMM) Q2 results are expected to reflect gains from the pandemic-induced demand for some products, buyout benefits and cost-saving measures. However, the pandemic scare might have ailed.
The Zacks Analyst Blog Highlights: Lakeland Industries, Honeywell International, 3M Company and MSA Safety
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Lakeland Industries, Honeywell International, 3M Company and MSA Safety
Honeywell (HON) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Honeywell (HON) is expected to have gained from its efforts to maximize productivity and a surge in demand for healthcare products. The pandemic-led issues will likely get reflected in its Q2 results.
3M (MMM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
3M (MMM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Danaher (DHR) Keep Its Earnings Streak Alive in Q2?
by Zacks Equity Research
Danaher's (DHR) Q2 results are anticipated to reflect healthy demand for some of its products and synergistic gains from Cytiva. Yet, subdued demand for a few other products is expected to have ailed.